TNXP
Tonix Pharmaceuticals Holding Corp.
There isn't enough reported data to score TNXP yet.
TNXP Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
TNXP's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
TNXP PE Valuation
TNXP has no meaningful PE right now: it lost money over the past year.
TNXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect TNXP's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TNXP Earnings Per Share
TNXP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.2M | +424% |
| Q2 2026 | $13.5M | +578% |
| Q1 2026 | $6.9M | +183% |
| Q4 2025 | $5.4M | +109% |
| Q3 2025 | $3.3M | +17% |
| Q2 2025 | $2M | -9.5% |
| Q1 2025 | $2.4M | -2.1% |
| Q4 2024 | $2.6M | -32% |
TNXP's revenue has grown year over year for five quarters in a row: $17M last quarter, up 424% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -322% | +683 points |
| Q2 2026 | -314% | +1102 points |
| Q1 2026 | -604% | +57 points |
| Q4 2025 | -896% | -25 points |
| Q3 2025 | -1005% | -454 points |
| Q2 2025 | -1416% | +2085 points |
| Q1 2025 | -661% | +199 points |
| Q4 2024 | -871% | -148 points |
TNXP's operating margin was −322% last quarter, up 683 points from the same quarter a year ago.
TNXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$41.7M | -$11.9M |
| Q2 2026 | -$42.8M | -$27.5M |
| Q1 2026 | -$44M | -$27.4M |
| Q4 2025 | -$41.5M | -$26.9M |
| Q3 2025 | -$29.7M | -$10.9M |
| Q2 2025 | -$15.4M | -$5.4M |
| Q1 2025 | -$16.6M | +$1.1M |
| Q4 2024 | -$14.6M | +$8.1M |
TNXP has burned cash in almost every quarter: −$170M over the past year, against −$76M the year before.
TNXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +1.8M shares |
| 1 year | +152% | +11.1M shares |
TNXP has 18M diluted shares, up 152% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $7.8M |
| Q3 2025 | — |
| Q2 2025 | $2.9M |
| Q1 2025 | $3M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $14M |
TNXP Net Leverage
TNXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TNXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 1.2 | Oversold |
TNXP's weekly RSI is 24 (oversold) and its Stochastic is 1 (oversold).
TNXP PE vs Healthcare Sector
TNXP has no meaningful PE right now: it lost money over the past year.
TNXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.29 | 48% below |
| 20 week MA | $9.72 | 67% below |
| 50 week MA | $12.7 | 74% below |
| 100 week MA | $20.0 | 84% below |
| 200 week MA | $1,860.9 | 100% below |
TNXP is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
TNXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $704,000.0 | $425,600.0 | -40% |
| 2021 | $425,600.0 | $256,064.0 | -40% |
| 2022 | $256,064.0 | $6,640.0 | -97% |
| 2023 | $6,640.0 | $1,289.6 | -81% |
| 2024 | $1,289.6 | $33.8 | -97% |
| 2025 | $33.8 | $16.3 | -52% |
| 2026 YTD | $16.3 | $3.24 | -80% |
TNXP has finished every year since 2020 lower, and it's down 80% so far in 2026.